Welcome to our dedicated page for Tenaya Therapeutics SEC filings (Ticker: TNYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tenaya Therapeutics, Inc. (NASDAQ: TNYA) SEC filings page provides access to the company’s publicly filed documents, including current reports on Form 8-K and other registration materials related to its clinical-stage biotechnology activities. Tenaya describes itself as a clinical-stage company developing gene therapies and a small molecule HDAC6 inhibitor that address the underlying drivers of heart disease, and its filings offer additional detail on these efforts.
Through its SEC reports, Tenaya discloses material events such as underwritten public offerings, clinical program updates and financial results. For example, a Form 8-K dated December 11, 2025, outlines the terms of an underwritten public offering of units consisting of common stock and warrants, including expected gross proceeds and key conditions. Other 8-K filings reference quarterly financial results and communications with the U.S. Food and Drug Administration regarding the MyPEAK-1 trial of TN-201.
Investors can use these filings to better understand capital structure changes, including equity offerings and warrant terms, as well as regulatory and clinical milestones that the company reports to the market. The filings also confirm Tenaya’s exchange listing on the Nasdaq Global Select Market under the symbol TNYA and describe the nature of its business as a clinical-stage biotechnology company focused on therapies for genetic cardiomyopathies and heart failure.
On Stock Titan, Tenaya’s filings are paired with AI-powered summaries that highlight key points from documents such as Form 8-K current reports and registration statements. This can help readers quickly identify the main elements of financing transactions, clinical trial disclosures and other material events, while still allowing full access to the original SEC text for detailed review.